Nimotuzumab in Adults With Glioblastoma Multiforma

Inclusion Criteria: * Patient signed informed consent * Newly diagnosed, histologically confirmed glioblastoma multiforme grade IV * Condition is measurable by MRI in at least one dimension * Age 18-70 * Karnofsky-Index \> 40 * Treatment in a study center * Female patients with a childbearing potential must have a negative pregnancy test within one week before inclusion in the trial. Those female and male patients admitted in the study must use a reliable method of contraception. * Adequate haematological, renal and hepatic function: * Leucocytes \>2.0x10\^9/l * Hb\> 10g/dl * Billirubin total \< 2.5x upper limit of normal (ULN) * Creatinin i.S. \< 1.5x ULN * AST (GOT)/ALT (GPT) \< 5x ULN Exclusion Criteria: * Patients with history of anaphylactic reaction to murine or humanized antibody * Patients with evidence second malignancy * Patients who are pregnant or patients who refused adequate contraceptive precaution (female and male) during the trial * Pregnancy and lactation * Other conditions considered by investigators as sound reasons for disqualification from enrolment into the study such as: potential non compliance with protocol requirement * No MRI for tumour evaluation